Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Kite Pharma, Inc. (KITE) since 2014 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Kite Pharma, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1510580.
Total stock buying since 2014: $5,803,660.
Total stock sales since 2014: $197,656,377.
Total stock option exercises since 2014: $15,164,987.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2017 | 81,682 | $5,667,660 | 875,902 | $81,791,822 | 502,849 | $10,948,384 |
| 2016 | 0 | $0 | 284,535 | $15,236,056 | 256,935 | $2,457,648 |
| 2015 | 0 | $0 | 1,630,944 | $100,628,499 | 457,678 | $1,758,955 |
| 2014 | 8,000 | $136,000 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2017-09 | 0 | $0 | 56,335 | $10,121,367 | 0 | $0 |
| 2017-08 | 0 | $0 | 119,200 | $14,014,283 | 110,200 | $5,062,899 |
| 2017-07 | 0 | $0 | 51,649 | $5,524,103 | 51,649 | $1,492,619 |
| 2017-06 | 0 | $0 | 97,850 | $8,960,339 | 24,900 | $570,244 |
| 2017-05 | 81,682 | $5,667,660 | 22,400 | $1,849,088 | 22,400 | $267,160 |
| 2017-04 | 0 | $0 | 280,857 | $23,206,120 | 22,400 | $156,360 |
| 2017-03 | 0 | $0 | 166,711 | $13,126,910 | 190,400 | $815,279 |
| 2017-02 | 0 | $0 | 59,400 | $3,907,762 | 59,400 | $2,546,488 |
| 2017-01 | 0 | $0 | 21,500 | $1,081,850 | 21,500 | $37,335 |
| 2016-12 | 0 | $0 | 18,100 | $920,988 | 4,500 | $31,005 |
| 2016-11 | 0 | $0 | 21,500 | $1,093,670 | 21,500 | $37,335 |
| 2016-10 | 0 | $0 | 1,500 | $82,672 | 1,500 | $10,335 |
| 2016-09 | 0 | $0 | 11,500 | $628,862 | 11,500 | $23,835 |
| 2016-08 | 0 | $0 | 47,400 | $2,834,516 | 47,400 | $1,870,172 |
| 2016-07 | 0 | $0 | 11,500 | $584,357 | 11,500 | $23,835 |
| 2016-06 | 0 | $0 | 35,500 | $1,904,466 | 21,500 | $37,335 |
| 2016-05 | 0 | $0 | 1,500 | $75,000 | 1,500 | $10,335 |
| 2016-04 | 0 | $0 | 10,000 | $500,000 | 10,000 | $13,500 |
| 2016-03 | 0 | $0 | 36,006 | $1,705,365 | 36,006 | $162,263 |
| 2016-02 | 0 | $0 | 48,217 | $2,562,997 | 48,217 | $94,035 |
| 2016-01 | 0 | $0 | 41,812 | $2,343,163 | 41,812 | $143,663 |
| 2015-12 | 0 | $0 | 43,712 | $2,901,293 | 43,712 | $146,228 |
| 2015-11 | 0 | $0 | 92,212 | $7,276,085 | 92,212 | $424,993 |
| 2015-10 | 0 | $0 | 51,412 | $3,167,659 | 51,412 | $199,281 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2017-09-25 | Jenkinson Paul L (Chief Financial Officer) | Sale | 948 | 179.66 | 170,321 |
| 2017-09-25 | Moore Timothy L. (EVP, Technical Operations) | Sale | 4,228 | 179.66 | 759,619 |
| 2017-09-25 | Tomasello Shawn (Chief Commercial Officer) | Sale | 4,203 | 179.66 | 755,127 |
| 2017-09-25 | Chang David D (EVP, R&D, Chief Medical Off.) | Sale | 7,927 | 179.66 | 1,424,196 |
| 2017-09-25 | Wiezorek Jeffrey (SVP Clinical Development) | Sale | 5,283 | 179.66 | 949,164 |
| 2017-09-25 | Kim Helen Susan (EVP, Business Development) | Sale | 3,171 | 179.66 | 569,714 |
| 2017-09-25 | Belldegrun Arie (Chairman, President and CEO) | Sale | 26,347 | 179.66 | 4,733,607 |
| 2017-09-25 | Butitta Cynthia M (Chief Operating Officer) | Sale | 4,228 | 179.66 | 759,619 |
| 2017-08-10 | Kim Helen Susan (EVP, Business Development) | Sale | 6,251 | 120.09 | 750,682 |
| 2017-08-10 | Kim Helen Susan (EVP, Business Development) | Option Ex | 6,251 | 52.66 | 329,208 |
| 2017-08-10 | Butitta Cynthia M (Chief Operating Officer) | Sale | 15,000 | 120.78 | 1,811,625 |
| 2017-08-10 | Butitta Cynthia M (Chief Operating Officer) | Option Ex | 15,000 | 1.35 | 20,250 |
| 2017-08-08 | Kim Helen Susan (EVP, Business Development) | Sale | 79,949 | 118.77 | 9,495,382 |
| 2017-08-08 | Kim Helen Susan (EVP, Business Development) | Option Ex | 79,949 | 53.90 | 4,309,251 |
| 2017-08-03 | Moore Timothy L. (EVP, Technical Operations) | Sale | 6,000 | 110.08 | 660,450 |
| 2017-08-03 | Moore Timothy L. (EVP, Technical Operations) | Option Ex | 6,000 | 44.91 | 269,460 |
| 2017-08-01 | Moore Timothy L. (EVP, Technical Operations) | Sale | 12,000 | 108.01 | 1,296,144 |
| 2017-08-01 | Moore Timothy L. (EVP, Technical Operations) | Option Ex | 3,000 | 44.91 | 134,730 |
| 2017-07-31 | Kim Helen Susan (EVP, Business Development) | Sale | 26,649 | 110.16 | 2,935,653 |
| 2017-07-31 | Kim Helen Susan (EVP, Business Development) | Option Ex | 26,649 | 52.66 | 1,403,469 |
| 2017-07-10 | Butitta Cynthia M (Chief Operating Officer) | Sale | 15,000 | 102.89 | 1,543,350 |
| 2017-07-10 | Butitta Cynthia M (Chief Operating Officer) | Option Ex | 15,000 | 1.35 | 20,250 |
| 2017-07-03 | Wiezorek Jeffrey (SVP Clinical Development) | Sale | 10,000 | 104.51 | 1,045,100 |
| 2017-07-03 | Wiezorek Jeffrey (SVP Clinical Development) | Option Ex | 10,000 | 6.89 | 68,900 |
| 2017-06-26 | Witte Owen N. (Director) | Sale | 12,500 | 100.60 | 1,257,500 |
| 2017-06-23 | Witte Owen N. (Director) | Sale | 12,500 | 100.00 | 1,250,000 |
| 2017-06-23 | Witte Owen N. (Director) | Option Ex | 12,500 | 34.66 | 433,312 |
| 2017-06-23 | Butitta Cynthia M (Chief Operating Officer) | Sale | 5,000 | 100.86 | 504,325 |
| 2017-06-16 | Champsi Farah (Director) | Sale | 5,450 | 88.11 | 480,199 |
| 2017-06-14 | Ruchefsky Steven B (Director) | Sale | 20,000 | 89.48 | 1,789,580 |
| 2017-06-14 | Champsi Farah (Director) | Sale | 15,000 | 90.40 | 1,356,000 |
| 2017-06-09 | Butitta Cynthia M (Chief Operating Officer) | Sale | 10,000 | 88.16 | 881,600 |
| 2017-06-09 | Butitta Cynthia M (Chief Operating Officer) | Option Ex | 10,000 | 1.35 | 13,500 |
| 2017-06-08 | Doumani Roy (Director) | Sale | 5,000 | 84.53 | 422,635 |
| 2017-06-07 | Doumani Roy (Director) | Sale | 10,000 | 84.46 | 844,620 |
| 2017-06-01 | Kim Helen Susan (EVP, Business Development) | Sale | 2,400 | 72.45 | 173,880 |
| 2017-06-01 | Kim Helen Susan (EVP, Business Development) | Option Ex | 2,400 | 51.43 | 123,432 |
| 2017-05-10 | Jenkinson Paul L (Chief Financial Officer) | Buy | 3,450 | 72.58 | 250,401 |
| 2017-05-09 | Nussbaum Ran (Director) | Buy | 9,832 | 69.11 | 679,519 |
| 2017-05-09 | Ruchefsky Steven B (Director) | Buy | 1,400 | 69.50 | 97,300 |
| 2017-05-09 | Belldegrun Arie (Chairman, President and CEO) | Buy | 17,000 | 68.57 | 1,165,690 |
| 2017-05-09 | Bonderman David (Director) | Buy | 50,000 | 69.50 | 3,474,750 |
| 2017-05-01 | Chang David D (EVP, R&D, Chief Medical Off.) | Sale | 20,000 | 82.60 | 1,652,000 |
| 2017-05-01 | Chang David D (EVP, R&D, Chief Medical Off.) | Option Ex | 20,000 | 6.89 | 137,800 |
| 2017-05-01 | Kim Helen Susan (EVP, Business Development) | Sale | 2,400 | 82.12 | 197,088 |
| 2017-05-01 | Kim Helen Susan (EVP, Business Development) | Option Ex | 2,400 | 53.90 | 129,360 |
| 2017-04-28 | Champsi Farah (Director) | Sale | 2,617 | 82.59 | 216,138 |
| 2017-04-27 | Champsi Farah (Director) | Sale | 16,551 | 82.77 | 1,369,926 |
| 2017-04-26 | Champsi Farah (Director) | Sale | 51,312 | 82.89 | 4,253,251 |
| 2017-04-25 | Butitta Cynthia M (Chief Operating Officer) | Sale | 15,000 | 81.97 | 1,229,505 |
| 2017-04-25 | Butitta Cynthia M (Chief Operating Officer) | Option Ex | 15,000 | 1.35 | 20,250 |
| 2017-04-25 | Champsi Farah (Director) | Sale | 46,783 | 82.92 | 3,879,480 |
| 2017-04-24 | Champsi Farah (Director) | Sale | 25,818 | 82.34 | 2,125,854 |
| 2017-04-17 | Champsi Farah (Director) | Sale | 43,101 | 82.77 | 3,567,469 |
| 2017-04-13 | Champsi Farah (Director) | Sale | 72,275 | 82.39 | 5,954,737 |
| 2017-04-03 | Kim Helen Susan (EVP, Business Development) | Sale | 2,400 | 81.80 | 196,320 |
| 2017-04-03 | Kim Helen Susan (EVP, Business Development) | Option Ex | 2,400 | 53.90 | 129,360 |
| 2017-04-03 | Butitta Cynthia M (Chief Operating Officer) | Sale | 5,000 | 82.69 | 413,440 |
| 2017-04-03 | Butitta Cynthia M (Chief Operating Officer) | Option Ex | 5,000 | 1.35 | 6,750 |
| 2017-03-27 | Butitta Cynthia M (Chief Operating Officer) | Sale | 10,000 | 77.45 | 774,550 |
| 2017-03-27 | Butitta Cynthia M (Chief Operating Officer) | Option Ex | 10,000 | 1.35 | 13,500 |
| 2017-03-15 | Moore Timothy L. (EVP, Technical Operations) | Sale | 7,511 | 83.31 | 625,741 |
| 2017-03-09 | Butitta Cynthia M (Chief Operating Officer) | Sale | 21,118 | 80.83 | 1,707,073 |
| 2017-03-09 | Butitta Cynthia M (Chief Operating Officer) | Option Ex | 21,118 | 1.35 | 28,509 |
| 2017-03-01 | Chang David D (EVP, R&D, Chief Medical Off.) | Sale | 60,000 | 79.41 | 4,764,600 |
| 2017-03-01 | Chang David D (EVP, R&D, Chief Medical Off.) | Option Ex | 60,000 | 6.89 | 413,400 |
| 2017-03-01 | Wiezorek Jeffrey (SVP Clinical Development) | Sale | 18,000 | 74.89 | 1,348,020 |
| 2017-03-01 | Wiezorek Jeffrey (SVP Clinical Development) | Option Ex | 18,000 | 6.89 | 124,020 |
| 2017-03-01 | Kim Helen Susan (EVP, Business Development) | Sale | 2,400 | 74.27 | 178,248 |
| 2017-03-01 | Kim Helen Susan (EVP, Business Development) | Option Ex | 2,400 | 53.90 | 129,360 |
| 2017-03-01 | Doumani Roy (Director) | Sale | 18,800 | 75.36 | 1,416,674 |
| 2017-03-01 | Doumani Roy (Director) | Option Ex | 50,000 | 1.35 | 67,500 |
| 2017-03-01 | Butitta Cynthia M (Chief Operating Officer) | Sale | 28,882 | 80.05 | 2,312,004 |
| 2017-03-01 | Butitta Cynthia M (Chief Operating Officer) | Option Ex | 28,882 | 1.35 | 38,990 |
| 2017-02-28 | Kim Helen Susan (EVP, Business Development) | Sale | 47,900 | 68.49 | 3,280,623 |
| 2017-02-28 | Kim Helen Susan (EVP, Business Development) | Option Ex | 47,900 | 52.66 | 2,522,653 |
| 2017-02-27 | Butitta Cynthia M (Chief Operating Officer) | Sale | 10,000 | 55.03 | 550,320 |
| 2017-02-27 | Butitta Cynthia M (Chief Operating Officer) | Option Ex | 10,000 | 1.35 | 13,500 |
| 2017-02-01 | Wiezorek Jeffrey (SVP Clinical Development) | Sale | 1,500 | 51.21 | 76,819 |
| 2017-02-01 | Wiezorek Jeffrey (SVP Clinical Development) | Option Ex | 1,500 | 6.89 | 10,335 |
| 2017-01-31 | Butitta Cynthia M (Chief Operating Officer) | Sale | 10,000 | 50.56 | 505,560 |
| 2017-01-31 | Butitta Cynthia M (Chief Operating Officer) | Option Ex | 10,000 | 1.35 | 13,500 |
| 2017-01-06 | Wiezorek Jeffrey (SVP Clinical Development) | Sale | 1,500 | 50.00 | 75,000 |
| 2017-01-06 | Wiezorek Jeffrey (SVP Clinical Development) | Option Ex | 1,500 | 6.89 | 10,335 |
| 2017-01-06 | Butitta Cynthia M (Chief Operating Officer) | Sale | 10,000 | 50.13 | 501,290 |
| 2017-01-06 | Butitta Cynthia M (Chief Operating Officer) | Option Ex | 10,000 | 1.35 | 13,500 |
| 2016-12-20 | Tomasello Shawn (Chief Commercial Officer) | Sale | 4,901 | 50.86 | 249,264 |
| 2016-12-20 | Chang David D (EVP, R&D, Chief Medical Off.) | Sale | 1,788 | 50.86 | 90,937 |
| 2016-12-20 | Kim Helen Susan (EVP, Business Development) | Sale | 936 | 50.86 | 47,604 |
| 2016-12-20 | Belldegrun Arie (Chairman, President and CEO) | Sale | 3,493 | 50.86 | 177,653 |
| 2016-12-20 | Butitta Cynthia M (Chief Operating Officer) | Sale | 2,482 | 50.86 | 126,234 |
| 2016-12-01 | Wiezorek Jeffrey (SVP Clinical Development) | Sale | 3,000 | 50.95 | 152,864 |
| 2016-12-01 | Wiezorek Jeffrey (SVP Clinical Development) | Option Ex | 3,000 | 6.89 | 20,670 |
| 2016-11-25 | Butitta Cynthia M (Chief Operating Officer) | Sale | 10,000 | 50.90 | 508,950 |
| 2016-11-25 | Butitta Cynthia M (Chief Operating Officer) | Option Ex | 10,000 | 1.35 | 13,500 |
| 2016-11-10 | Wiezorek Jeffrey (SVP Clinical Development) | Sale | 1,500 | 50.18 | 75,270 |
| 2016-11-10 | Wiezorek Jeffrey (SVP Clinical Development) | Option Ex | 1,500 | 6.89 | 10,335 |
| 2016-11-10 | Butitta Cynthia M (Chief Operating Officer) | Sale | 10,000 | 50.95 | 509,450 |
| 2016-11-10 | Butitta Cynthia M (Chief Operating Officer) | Option Ex | 10,000 | 1.35 | 13,500 |
| 2016-10-03 | Wiezorek Jeffrey (SVP Clinical Development) | Sale | 1,500 | 55.12 | 82,672 |
| 2016-10-03 | Wiezorek Jeffrey (SVP Clinical Development) | Option Ex | 1,500 | 6.89 | 10,335 |
| 2016-09-26 | Butitta Cynthia M (Chief Operating Officer) | Sale | 10,000 | 54.13 | 541,300 |
| 2016-09-26 | Butitta Cynthia M (Chief Operating Officer) | Option Ex | 10,000 | 1.35 | 13,500 |
| 2016-09-01 | Wiezorek Jeffrey (SVP Clinical Development) | Sale | 1,500 | 58.38 | 87,562 |
| 2016-09-01 | Wiezorek Jeffrey (SVP Clinical Development) | Option Ex | 1,500 | 6.89 | 10,335 |
| 2016-08-25 | Butitta Cynthia M (Chief Operating Officer) | Sale | 10,000 | 58.52 | 585,250 |
| 2016-08-25 | Butitta Cynthia M (Chief Operating Officer) | Option Ex | 10,000 | 1.35 | 13,500 |
| 2016-08-15 | Kim Helen Susan (EVP, Business Development) | Sale | 2,400 | 63.01 | 151,228 |
| 2016-08-15 | Kim Helen Susan (EVP, Business Development) | Option Ex | 2,400 | 51.43 | 123,432 |
| 2016-08-12 | Kim Helen Susan (EVP, Business Development) | Sale | 33,500 | 60.08 | 2,012,613 |
| 2016-08-12 | Kim Helen Susan (EVP, Business Development) | Option Ex | 33,500 | 51.43 | 1,722,905 |
| 2016-08-01 | Wiezorek Jeffrey (SVP Clinical Development) | Sale | 1,500 | 56.95 | 85,425 |
| 2016-08-01 | Wiezorek Jeffrey (SVP Clinical Development) | Option Ex | 1,500 | 6.89 | 10,335 |
| 2016-07-25 | Butitta Cynthia M (Chief Operating Officer) | Sale | 10,000 | 50.94 | 509,350 |
| 2016-07-25 | Butitta Cynthia M (Chief Operating Officer) | Option Ex | 10,000 | 1.35 | 13,500 |
| 2016-07-01 | Wiezorek Jeffrey (SVP Clinical Development) | Sale | 1,500 | 50.01 | 75,007 |
| 2016-07-01 | Wiezorek Jeffrey (SVP Clinical Development) | Option Ex | 1,500 | 6.89 | 10,335 |
| 2016-06-27 | Butitta Cynthia M (Chief Operating Officer) | Sale | 10,000 | 50.15 | 501,480 |
| 2016-06-27 | Butitta Cynthia M (Chief Operating Officer) | Option Ex | 10,000 | 1.35 | 13,500 |
| 2016-06-23 | Butitta Cynthia M (Chief Operating Officer) | Sale | 10,000 | 51.27 | 512,750 |
| 2016-06-23 | Butitta Cynthia M (Chief Operating Officer) | Option Ex | 10,000 | 1.35 | 13,500 |
| 2016-06-06 | Doumani Roy (Director) | Sale | 14,000 | 58.06 | 812,896 |
| 2016-06-01 | Wiezorek Jeffrey (SVP Clinical Development) | Sale | 1,500 | 51.56 | 77,340 |
| 2016-06-01 | Wiezorek Jeffrey (SVP Clinical Development) | Option Ex | 1,500 | 6.89 | 10,335 |
| 2016-05-31 | Wiezorek Jeffrey (SVP Clinical Development) | Sale | 1,500 | 50.00 | 75,000 |
| 2016-05-31 | Wiezorek Jeffrey (SVP Clinical Development) | Option Ex | 1,500 | 6.89 | 10,335 |
| 2016-04-04 | Butitta Cynthia M (COO and CFO) | Sale | 10,000 | 50.00 | 500,000 |
| 2016-04-04 | Butitta Cynthia M (COO and CFO) | Option Ex | 10,000 | 1.35 | 13,500 |
| 2016-03-15 | Wiezorek Jeffrey (SVP Clinical Development) | Sale | 9,000 | 46.05 | 414,432 |
| 2016-03-15 | Wiezorek Jeffrey (SVP Clinical Development) | Option Ex | 9,000 | 6.89 | 62,010 |
| 2016-03-15 | Sproule Rizwana F (VP Regulatory Affairs) | Sale | 8,500 | 46.58 | 395,930 |
| 2016-03-15 | Sproule Rizwana F (VP Regulatory Affairs) | Option Ex | 8,500 | 1.35 | 11,475 |
| 2016-03-15 | Roberts Margo R (Chief Scientific Officer) | Sale | 8,506 | 46.40 | 394,703 |
| 2016-03-15 | Roberts Margo R (Chief Scientific Officer) | Option Ex | 8,506 | 8.85 | 75,278 |
| 2016-03-01 | Butitta Cynthia M (COO and CFO) | Sale | 10,000 | 50.03 | 500,300 |
| 2016-03-01 | Butitta Cynthia M (COO and CFO) | Option Ex | 10,000 | 1.35 | 13,500 |
| 2016-02-17 | Sproule Rizwana F (VP Regulatory Affairs) | Sale | 9,567 | 45.54 | 435,681 |
| 2016-02-17 | Sproule Rizwana F (VP Regulatory Affairs) | Option Ex | 9,567 | 1.35 | 12,915 |
| 2016-02-16 | Wiezorek Jeffrey (SVP Clinical Development) | Sale | 9,000 | 44.23 | 398,115 |
| 2016-02-16 | Wiezorek Jeffrey (SVP Clinical Development) | Option Ex | 9,000 | 6.89 | 62,010 |
| 2016-02-12 | Roberts Margo R (Chief Scientific Officer) | Sale | 18,750 | 64.16 | 1,202,962 |
| 2016-02-12 | Roberts Margo R (Chief Scientific Officer) | Option Ex | 18,750 | .70 | 13,125 |
| 2016-02-02 | Butitta Cynthia M (COO and CFO) | Sale | 1,900 | 50.13 | 95,247 |
| 2016-02-02 | Butitta Cynthia M (COO and CFO) | Option Ex | 1,900 | 1.35 | 2,565 |
| 2016-02-01 | Better Marc (VP, Product Sciences) | Sale | 9,000 | 47.89 | 430,992 |
| 2016-02-01 | Better Marc (VP, Product Sciences) | Option Ex | 9,000 | .38 | 3,420 |
| 2016-01-27 | Butitta Cynthia M (COO and CFO) | Sale | 8,100 | 51.95 | 420,778 |
| 2016-01-27 | Butitta Cynthia M (COO and CFO) | Option Ex | 8,100 | 1.35 | 10,935 |
| 2016-01-19 | Sproule Rizwana F (VP Regulatory Affairs) | Sale | 2,767 | 56.19 | 155,486 |
| 2016-01-19 | Sproule Rizwana F (VP Regulatory Affairs) | Option Ex | 2,767 | 1.35 | 3,735 |
Insider trading activities including stock purchases, stock sales, and option exercises of KITE listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Kite Pharma, Inc. (symbol KITE, CIK number 1510580) see the Securities and Exchange Commission (SEC) website.